Industry P pharmaphorum
The PM Awards aren’t just for agencies. They’re for the people who make great work happen
The PM Awards aren’t just for agencies. They’re for the people who make great work happen Sara.Scarpinati Wed, 11/11/2026 - 11:11
The latest biotech and pharma news from the trade press, updated every hour and linked straight to the publisher. Follow funding, clinical, deals and more. Every story links straight to its publisher.
Industry P pharmaphorum
The PM Awards aren’t just for agencies. They’re for the people who make great work happen Sara.Scarpinati Wed, 11/11/2026 - 11:11
Industry P pharmaphorum
AZ boosts vaccine capabilities with Omniose buy Phil.Taylor Wed, 11/11/2026 - 11:02
Regulatory A Applied Clinical Trials
FDA and EMA expectations shape how sponsors use CGM in diabetes trials, from blinding and study-provisioned devices to data integrity and ePRO integration.
Clinical P Pharmaceutical Executive
AI can make clinical trials smarter and faster, but lived patient experience remains irreplaceable in guiding research toward optimal results.
Regulatory A Applied Clinical Trials
In today’s ACT Brief, we examine why APAC is attractive for global Phase III programs, how clinical research professionals can turn a failed pivotal trial into a redesigned success, and how FDA approved Sunharbo to reduce recurrent stroke risk.
Research E EMBL
The award will support the development of new translational research projects in collaboration with partners in the Lombardy region of Italy.
Industry
Pharmaceutical Technology
ProBio has entered into an exclusive worldwide licensing agreement with South Korean biotechnology firm AbTis to develop and commercialise an early-stage therapeutic antibody asset.
Clinical
Clinical Trials Arena
Natera and Incyte have entered into a clinical collaboration to conduct an interventional Phase II study of INCA33890 in colorectal cancer. The post Natera and Incyte partner on Phase II colorectal cancer trial appeared first on Clinical Trials Arena.
Clinical
Clinical Trials Arena
China may be on pace to close its gap with the US in global biopharma, but only if it can clear the last few hurdles. The post OCT New England 2026: the next phase in China’s rise appeared first on Clinical Trials Arena.
Regulatory P pharmaphorum
Merck's rare tumour drug Pimjetmi claims FDA approval Phil.Taylor Wed, 11/11/2026 - 10:00
Industry
Clinical Trials Arena
The US midterms will result in increased power for the Democrats, but experts don't foresee significant healthcare policy changes. The post Democrat midterm landslide spells greater Trump oversight, marginal reforms appeared first on Clinical Trials Arena.
Funding
Pharmaceutical Technology
Oyster Therapeutics has closed a $60m Series A-2 financing round to advance targeted protein degraders for neurodegenerative diseases including Alzheimer’s.
Clinical
Clinical Trials Arena
Lipocine has dosed the first patient in its Phase III BLOOM clinical study assessing LPCN 1154 for the treatment of PPD. The post Lipocine doses first patient in Phase III postpartum depression study appeared first on Clinical Trials Arena.
Clinical P Pharmafile
Qureight has published a peer-reviewed paper arguing that the extent of pulmonary fibrosis should be considered the principal structural imaging biomarker in clinical trials of antifibrotic treatments. The Viewpoint, published in the European Respiratory Journal, makes the case f…
Clinical P pharmaphorum
Antiviral development in the age of AI: From pre-IND to early stage human trials Nicole.Raleigh Wed, 11/11/2026 - 08:00
Industry E EUCOPE
As the implementation of the EU Health Technology Assessment (HTA) Regulation gathers pace, its practical implications for pharmaceutical companies are becoming increasingly tangible. The first Joint Clinical Assessment (JCA) has already entered Germany’s national AMNOG process,…
Software M MetaphysicalCells
Welcome back to another edition of MetaphysicalCellsThis Substack is reader-supported.
Agriculture P Patent Docs
By Kevin E. Noonan – The province of the post-grant review (PGR) provisions of the Leahy-Smith America Invents Act under 35 U.S.C. §§ 321–329 permits a challenger to assert invalidity for anticipation under 35 U.S.C. § 102 and obviousness under 35 U.S.C. § 103 (among other provis…
Regulatory F FDA Law Blog
By Adrienne R. Lenz, Principal Medical Device Regulation Expert —
Software W Weekly Tech+Bio
ALSO: argenx pays $550M upfront for AI-designed oral macrocycles; Third Rock signs an up-to-$2.16B AI antibody pact with China's Funnel Bio; AI agents run 11,000 wet-lab steps, and more...
Clinical
BioCentury
BIOCENTURY | PRODUCT DEVELOPMENTPEPGEN’S DM1 READOUT HINTS AT FUNCTIONAL PAYOFF FROM SPLICING CORRECTIONHigher dose of peptide-oligo conjugate produced substantial splicing correction alongside improvements in myotonia and grip strength
Industry N Nature Biomedical Engineering
Industry N Nature Medicine
Clinical N Nature Medicine
Regulatory
Nature Reviews Drug Discovery
Research
Nature Reviews Drug Discovery
Industry
BioCentury
BIOCENTURY | PRODUCT DEVELOPMENTSITC 2026: DUAL TARGETING, PRECISE INTEGRATION SHAPE IN VIVO CAR T DEVELOPMENTAt least 10 abstracts describe strategies to limit antigen escape and sustain CAR expression
Software
Ground Truths
A recording from Eric Topol's live video with annotations below
Industry
Fierce Biotech
Building resilient biomanufacturing supply networks scox Tue, 11/10/2026 - 17:22
Regulatory
BioCentury
BIOCENTURY | DATA BYTEFDA APPROVALS ON TRACK FOR RECORD YEARWith 47 approvals through October, CDER has already approved more drugs than in 35 of the past 41 years
Industry
BioPharma Dive
While from a small study, the findings suggest PepGen’s therapy compares favorably to other RNA-based medicines in testing at Novartis and Dyne Therapeutics.
Industry
Drug Discovery and Development
PROTACs (proteolysis-targeting chimeras) are an emerging class of drug molecules designed to eliminate disease-causing proteins rather than simply block them. Each PROTAC has two binding ends joined by a chemical linker: one end attaches to the target protein, while the other rec…
Regulatory
MedCity News
Bayer’s asundexian, brand name Sunharbo, is the first FDA-approved drug in a new class cardiovascular medicines Approval of the once-daily pill covers secondary stroke prevention in adults. The post FDA Approves First-in-Class Bayer Drug for Reducing the Risk of Stroke appeared f…
Funding
TechCrunch Biotech and Health
Former SignalFire investor Sahir Raoof raises $27.5M for new fund targeting AI in pharma
Manufacturing
Fierce Pharma
The Multi-Vendor Problem in Specialty Pharma -- and Why Manufacturers Are Consolidating Multiple vendors can create bottlenecks, fragmented data, and delays in specialty pharma. Discover how a unified model can improve visibility, enable proactive patient support, and reduce time…
Manufacturing
Fierce Biotech
The Multi-Vendor Problem in Specialty Pharma -- and Why Manufacturers Are Consolidating Multiple vendors can create bottlenecks, fragmented data, and delays in specialty pharma. Discover how a unified model can improve visibility, enable proactive patient support, and reduce time…
Clinical A Applied Clinical Trials
A pivotal trial that missed its primary endpoint became the basis for a successful redesign after the team used the data to define the high-risk patients most likely to benefit, showing that setbacks can strengthen development when organizations interrogate the evidence rather th…
Regulatory P Pharmaceutical Executive
FDA approves Bayer’s asundexian as the first Factor XIa inhibitor for secondary stroke prevention, the FDA requires a new safety label warning across all GLP-1 receptor agonists for a potential NAION risk, and AstraZeneca acquires Omniose to add a bioconjugation platform to its v…
Agriculture
CropLife
As biological technologies expand seed treatment capabilities, ag retailers can boost seed treatment value with benefits growers will pay for — if they get it right. The post The Seed Treatment Performance Test appeared first on CropLife.
Agriculture
CropLife
Discover what's driving grower purchasing behavior and how ag retailers can adapt their sales, inventory, and customer engagement strategies. The post 4 Reasons Why Farmers Are Waiting Longer to Make Input Decisions appeared first on CropLife.